Michael F Press

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. doi request reprint HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
    Clin Cancer Res 14:7861-70. 2008
  2. doi request reprint HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
    Mol Cancer Ther 16:228-238. 2017
  3. pmc HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
    Michael F Press
    Michael F Press, Denice D Tsao Wei, Yanling Ma, Ivonne Villalobos, and Anaamika Campeau, University of Southern California Norris Comprehensive Cancer Center Dennis J Slamon, Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA Nicholas Robert, Virginia Cancer Specialists US Oncology Research Network, Fairfax, VA Vicente Valero, The University of Texas MD Anderson Cancer Center, Houston, TX Guido Sauter and Martina Mirlacher, University of Hamburg, Hamburg Wolfgang Eiermann, Frauenklinik vom Roten Kreuz, Munich, Germany Marc Buyse, Hélène Fourmanoir, and Emmanuel Quinaux, International Drug Development Institute, Louvain la Neuve, Belgium Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland John Crown, Irish Cooperative Onoclogy Research Group, St Vincent s University Hospital, Dublin, Ireland Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain John R Mackey, Jiangxi Agricultural University
    J Clin Oncol . 2016
  4. pmc Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status
    Huiyan Ma
    Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA
    BMC Cancer 13:225. 2013
  5. pmc Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
    Nuran Bektas Serce
    Department of Pathology, University Hospital Bonn, Sigmund Freud Str 25, 53127 Bonn, Germany
    BMC Cancer 12:597. 2012
  6. pmc The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer
    Nuran Bektas
    Department of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
    Breast Cancer Res 10:R58. 2008
  7. pmc Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, CA, USA
    J Clin Oncol 29:859-67. 2011
  8. doi request reprint Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations
    Guido Sauter
    Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
    J Clin Oncol 27:1323-33. 2009
  9. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009
  10. pmc Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh,
    Arch Pathol Lab Med 138:241-56. 2014

Detail Information

Publications47

  1. doi request reprint HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
    Clin Cancer Res 14:7861-70. 2008
    ..Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy...
  2. doi request reprint HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
    Mol Cancer Ther 16:228-238. 2017
    ..While HER2 genomic heterogeneity occurs, its prevalence is low. Mol Cancer Ther; 16(1); 228-38. ©2016 AACR...
  3. pmc HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
    Michael F Press
    Michael F Press, Denice D Tsao Wei, Yanling Ma, Ivonne Villalobos, and Anaamika Campeau, University of Southern California Norris Comprehensive Cancer Center Dennis J Slamon, Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA Nicholas Robert, Virginia Cancer Specialists US Oncology Research Network, Fairfax, VA Vicente Valero, The University of Texas MD Anderson Cancer Center, Houston, TX Guido Sauter and Martina Mirlacher, University of Hamburg, Hamburg Wolfgang Eiermann, Frauenklinik vom Roten Kreuz, Munich, Germany Marc Buyse, Hélène Fourmanoir, and Emmanuel Quinaux, International Drug Development Institute, Louvain la Neuve, Belgium Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland John Crown, Irish Cooperative Onoclogy Research Group, St Vincent s University Hospital, Dublin, Ireland Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain John R Mackey, Jiangxi Agricultural University
    J Clin Oncol . 2016
    ..We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes...
  4. pmc Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status
    Huiyan Ma
    Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA
    BMC Cancer 13:225. 2013
    ..Furthermore, it is not known whether additional consideration of p53 protein status influences black-white differences in mortality risk observed when considering subtypes defined by ER, PR and HER2 status...
  5. pmc Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
    Nuran Bektas Serce
    Department of Pathology, University Hospital Bonn, Sigmund Freud Str 25, 53127 Bonn, Germany
    BMC Cancer 12:597. 2012
    ..This is the first study to present a systematic characterisation of SERBP1 expression in human breast cancer and normal breast tissue at both the mRNA and the protein level...
  6. pmc The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer
    Nuran Bektas
    Department of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
    Breast Cancer Res 10:R58. 2008
    ..To the best of our knowledge, in the current study we present for the first time a systematic characterisation of ISG15 expression in human breast cancer and normal breast tissue both at the mRNA and protein level...
  7. pmc Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, CA, USA
    J Clin Oncol 29:859-67. 2011
    ..This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers...
  8. doi request reprint Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations
    Guido Sauter
    Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
    J Clin Oncol 27:1323-33. 2009
    ..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies...
  9. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009
    ..We examined the prognostic and predictive role of HER2 ECD in a randomized trial of paclitaxel with placebo or lapatinib in women with HER2-negative or -unknown breast cancer...
  10. pmc Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh,
    Arch Pathol Lab Med 138:241-56. 2014
    ....
  11. pmc A genome-wide association study of breast cancer in women of African ancestry
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Hum Genet 132:39-48. 2013
    ..Identification of novel risk variants for breast cancer in women of African ancestry will demand testing of a substantially larger set of markers from stage 1 in a larger replication sample...
  12. ncbi request reprint Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
    Michael F Press
    Women s Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
    Clin Cancer Res 11:6598-607. 2005
    ....
  13. doi request reprint Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer
    Huiyan Ma
    Division of Cancer Etiology, Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA
    Cancer Epidemiol Biomarkers Prev 18:479-85. 2009
    ....
  14. pmc Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
    Richard S Finn
    Geffen School of Medicine at University of California, Los Angeles, CA, USA
    J Clin Oncol 27:3908-15. 2009
    ..Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib...
  15. pmc A genome-wide scan for breast cancer risk haplotypes among African American women
    Chi Song
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    PLoS ONE 8:e57298. 2013
    ....
  16. pmc A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    Nat Genet 43:1210-4. 2011
    ..25, P = 1.1 × 10(-9)), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10(-9)). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations...
  17. pmc Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
    BMC Cancer 9:43. 2009
    ....
  18. ncbi request reprint Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice
    Michael F Press
    From the Departments of Pathology Drs Press and Ma Mss Villalobos, Santiago, Guzmán, Cervantes, and Campeau and Mr Gasparyan and Preventive Medicine Ms Tsao Wei and Dr Groshen, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
    Arch Pathol Lab Med . 2016
    ....
  19. pmc Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women
    Veronica Wendy Setiawan
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Cancer Genet Cytogenet 181:16-9. 2008
    ..18, 95% CI = 0.76-1.82, P = 0.46). Our results do not support the hypothesis that the mtDNA G10398A polymorphism is, as has previously been reported, a marker of breast cancer risk in African Americans...
  20. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
    ..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer...
  21. doi request reprint Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:149-56. 2011
    ..Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC...
  22. doi request reprint Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial
    J Randolph Hecht
    J Randolph Hecht, Zev A Wainberg, and Dennis Slamon, David Geffen School of Medicine, University of California Los Angeles, Santa Monica Michael F Press, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA Yung Jue Bang, Seoul National University College of Medicine Hyun C Chung, Yonsei Cancer Center, Yonsei Cancer Research Institute, Yonsei University College of Medicine Joon O Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Shukui K Qin, People s Liberation Army Cancer Center, Nanjing Bayi Hospital, Jiangsu Jianming M Xu, Affiliated Hospital of the Military Medical Science Academy, Beijing Jin Li, Cancer Hospital of Shanghai Fudan University, Shanghai, People s Republic of China Krzysztof Jeziorski, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland Yaroslav Shparyk, Lviv State Regional Oncology Medical and Diagnostic Center, Lviv, Ukraine Paulo M Hoff, Sociedade Beneficente de Senhoras Hospital Sírio Libanês, Sao Paolo, Brazil Alberto Sobrero, Istituto di Ricovero e Cura a Carattere Scientifico San Martino Istituto Scientifico Tumori, Genova, Department of Physiology
    J Clin Oncol 34:443-51. 2016
    ..To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma...
  23. ncbi request reprint Lifetime recreational exercise activity and breast cancer risk among black women and white women
    Leslie Bernstein
    Department of Preventive Medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
    J Natl Cancer Inst 97:1671-9. 2005
    ....
  24. ncbi request reprint Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    Michael F Press
    Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
    J Clin Oncol 20:3095-105. 2002
    ..To compare and evaluate HER-2/neu clinical assay methods...
  25. ncbi request reprint A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans
    Christopher A Haiman
    Departments of Preventive Medicine and Pathology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Cancer Res 67:3565-8. 2007
    ..03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56-4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk...
  26. pmc Serum organochlorines and breast cancer: a case-control study among African-American women
    Nicole M Gatto
    Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, USC Norris Comprehensive Center, 1441 Eastlake Avenue, Room 4449, Los Angeles, CA 90033, USA
    Cancer Causes Control 18:29-39. 2007
    ..This study, the largest study of African-American women to date, does not support a role of DDE and total PCBs in breast cancer risk at the levels measured...
  27. pmc Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Hum Mol Genet 20:4491-503. 2011
    ..04, P = 6.1 × 10(-5)]. In this detailed analysis of the known breast cancer risk loci, we have validated and improved upon markers of risk that better characterize their association with breast cancer in women of African ancestry...
  28. ncbi request reprint EGFR, HER2 and VEGF pathways: validated targets for cancer treatment
    Michael F Press
    Department of Pathology, Keck School of Medicine, Oncology, University of Southern California Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA
    Drugs 67:2045-75. 2007
    ..The results achieved with targeted therapies to date are promising, although they illustrate the need for additional preclinical and clinical study...
  29. pmc A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry
    Keri L Monda
    The Center for Observational Research, Amgen, Inc Thousand Oaks, California, USA
    Nat Genet 45:690-6. 2013
    ..7 × 10(-7)), five of which reached genome-wide significance. These findings provide strong support for shared BMI loci across populations, as well as for the utility of studying ancestrally diverse populations...
  30. doi request reprint HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
    Peter A Fasching
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Breast Cancer Res Treat 145:193-203. 2014
    ....
  31. doi request reprint Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
    Chee Khoon Lee
    Chee Khoon Lee, Lucy Davies, Val J Gebski, Sarah J Lord, Ian Marschner, and John Simes, University of Sydney Sarah J Lord, University of Notre Dame Ian Marschner, Macquarie University Paul de Souza, University of Western Sydney, Sydney, New South Wales Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Angelo Di Leo, Hospital of Prato, Istituto Toscano Tumori, Italy Stephen Johnston, Royal Marsden Hospital, London David Cameron, University of Edinburgh, Edinburgh, United Kingdom Charles Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA Michael F Press, University of Southern California, Los Angeles, CA and Catherine Ellis, GlaxoSmithKline, Collegeville, PA
    J Clin Oncol 34:936-44. 2016
    ..We examined the prognostic and predictive value of serum human epidermal growth factor 2 (HER2) extracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data from three randomized trials...
  32. ncbi request reprint Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 17:315-23. 2004
    ..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system...
  33. pmc Methodological Considerations in Estimation of Phenotype Heritability Using Genome-Wide SNP Data, Illustrated by an Analysis of the Heritability of Height in a Large Sample of African Ancestry Adults
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States of America
    PLoS ONE 10:e0131106. 2015
    ..We conclude that today's GWAS data will remain useful in the future for causal variant prediction, but that finding the causal variants that need to be predicted may be extremely laborious. ..
  34. pmc Pathological characteristics of BRCA-associated breast cancers in Hispanics
    Veronica I Lagos-Jaramillo
    Division of Clinical Cancer Genetics, City of Hope, Duarte, CA, 91010, USA
    Breast Cancer Res Treat 130:281-9. 2011
    ..Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted as it could have important implications for the treatment and prevention of breast cancer in Hispanics...
  35. pmc Receptor tyrosine kinase EphB4 is a survival factor in breast cancer
    S Ram Kumar
    Department of Pathology, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, NOR 6330, Los Angeles, CA 90033, USA
    Am J Pathol 169:279-93. 2006
    ..Our data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy...
  36. ncbi request reprint Antibody-mediated targeting of replication-competent retroviral vectors
    Chien Kuo Tai
    Institute for Genetic Medicine, Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Hum Gene Ther 14:789-802. 2003
    ..Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design...
  37. pmc Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis
    Huiyan Ma
    Department of Population Sciences, Beckman Research Institute, 1500 East Duarte Rd Duarte, City of Hope, CA, 91010, USA
    Breast Cancer Res 19:6. 2017
    ..However, among breast cancer subtypes, it remains unclear whether all of these are risk factors for triple-negative breast cancer (TNBC)...
  38. doi request reprint Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC)
    Oliver A Press
    Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA
    Methods Mol Biol 1180:181-207. 2014
    ..This chapter provides a brief overview of pre-analytic and analytical processing of breast specimens as well as subsequent molecular evaluation for HER2 status...
  39. doi request reprint Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
    Richard S Finn
    Authors Affiliations Geffen School of Medicine at UCLA Norris Cancer Center, University of Southern California, Los Angeles, California GlaxoSmithKline, Collegeville, Pennsylvania GlaxoSmithKline, Durham, North Carolina and Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 20:736-43. 2014
    ..The hypothesis that low hormone receptor status is associated with benefit in this HER2-negative cohort was tested...
  40. pmc Genome-scale screen for DNA methylation-based detection markers for ovarian cancer
    Mihaela Campan
    Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS ONE 6:e28141. 2011
    ..We developed a systematic multi-step biomarker discovery and verification strategy to identify candidate DNA methylation markers for the blood-based detection of ovarian cancer...
  41. ncbi request reprint Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    David B Agus
    Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 23:2534-43. 2005
    ..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy...
  42. ncbi request reprint Lifetime recreational exercise activity and risk of breast carcinoma in situ
    Alpa V Patel
    Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Cancer 98:2161-9. 2003
    ..Because of its potential effects on circulating sex hormones, physical activity has been proposed as a modifiable risk factor for invasive breast carcinoma. However, the relation to BCIS risk is poorly understood...
  43. ncbi request reprint A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
    Kristin A Rand
    Keck School of Medicine of USC and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
    Cancer Epidemiol Biomarkers Prev 25:1609-1618. 2016
    ..Genome-wide association studies (GWAS) in European populations have identified genetic risk variants associated with multiple myeloma...
  44. doi request reprint Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, The Boston Consulting Group
    J Clin Oncol 31:3997-4013. 2013
    ....
  45. pmc Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial
    Linda Hovanessian-Larsen
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Contraception 86:238-43. 2012
    ....
  46. ncbi request reprint P7 antigen expression in human breast cancer
    Xiaowei Yang
    Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 9:201-6. 2003
    ..Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression...
  47. ncbi request reprint Identification of TP53 mutations in human cancers using oligonucleotide microarrays
    Wen Hsiang Wen
    Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Methods Mol Med 97:323-35. 2004